trending Market Intelligence /marketintelligence/en/news-insights/trending/5wwpxekywio6uzpgleozaw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Sumitomo Dainippon in ¥3.7B deal for drug to treat central nervous disease

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Sumitomo Dainippon in ¥3.7B deal for drug to treat central nervous disease

Sumitomo Dainippon Pharma Co. Ltd. will pay up to ?3.7 billion for the right to develop a substance using JCR Pharmaceuticals Co. Ltd.'s technology.

The payment is made up of an unspecified upfront amount plus further consideration related to the achievement of certain milestones.

JCR's J-Brain Cargo blood-brain barrier penetration technology is used in creating therapeutic agents for central nervous system diseases, including JR-141, which is being studied as a treatment for Hunter syndrome.

Sumitomo Dainippon, which is based in Japan, will have the rights to market the substance in the country, as well as North America. It may opt to secure the rights to the drug in China as well.

JCR Pharmaceuticals, which is also based in Japan, will also receive royalties on the sales of the drug once it is commercialized.

As of Feb. 23, US$1 was equivalent to 106.64 Japanese yen.